Indivior PLC (NASDAQ:INDV) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Indivior PLC (NASDAQ:INDV) has earned a consensus rating of “Moderate Buy” from the seven research firms that are covering the company, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $39.3333.

A number of research analysts recently issued reports on INDV shares. Piper Sandler restated an “overweight” rating and set a $41.00 price target (up previously from $27.00) on shares of Indivior in a report on Friday, October 31st. Weiss Ratings restated a “hold (c)” rating on shares of Indivior in a report on Wednesday, January 28th. Craig Hallum reaffirmed a “buy” rating and issued a $41.00 price target on shares of Indivior in a research note on Friday, October 31st. Northland Securities set a $50.00 price objective on shares of Indivior in a research report on Tuesday, January 20th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $36.00 target price on shares of Indivior in a research report on Wednesday, December 3rd.

Indivior Trading Down 0.3%

INDV stock opened at $34.36 on Friday. The stock has a market capitalization of $4.30 billion, a price-to-earnings ratio of 37.35 and a beta of 0.80. The firm’s 50-day moving average price is $34.95 and its two-hundred day moving average price is $28.49. Indivior has a 12-month low of $7.62 and a 12-month high of $38.00.

Insider Buying and Selling

In related news, Director Barbara Ryan acquired 775 shares of the stock in a transaction on Monday, January 5th. The stock was acquired at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the completion of the acquisition, the director directly owned 1,963 shares of the company’s stock, valued at approximately $69,470.57. This represents a 65.24% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David E. Wheadon bought 1,771 shares of Indivior stock in a transaction on Monday, January 5th. The shares were purchased at an average price of $35.39 per share, for a total transaction of $62,675.69. Following the acquisition, the director directly owned 14,395 shares in the company, valued at approximately $509,439.05. This trade represents a 14.03% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 4,871 shares of company stock valued at $172,385 over the last quarter.

Institutional Trading of Indivior

A number of hedge funds and other institutional investors have recently modified their holdings of INDV. Legato Capital Management LLC purchased a new position in Indivior during the 4th quarter valued at about $468,000. LSV Asset Management increased its stake in shares of Indivior by 1,334.2% during the fourth quarter. LSV Asset Management now owns 291,134 shares of the company’s stock valued at $10,446,000 after purchasing an additional 270,834 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Indivior by 2,930.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,485 shares of the company’s stock valued at $269,000 after purchasing an additional 7,238 shares in the last quarter. ProShare Advisors LLC lifted its holdings in shares of Indivior by 15.7% during the fourth quarter. ProShare Advisors LLC now owns 29,139 shares of the company’s stock valued at $1,046,000 after purchasing an additional 3,949 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund bought a new stake in shares of Indivior in the 4th quarter worth approximately $1,026,000. 60.33% of the stock is owned by hedge funds and other institutional investors.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.